Monday, April 20, 2015 2:34:24 PM
As the smart money reads the tea leaves (publicly available data on MNTA's FDA application/ data from the extensive legal record/ the steep wall faced by other generic copaxone applications), I think it inevitable that they will see this stock as tremendously undervalued. It won't remain that way.
The immediate post-approval 'pop' was understandably undercut by disappointed longs running for the exits -- but will still going to occur. A fresh look by smart eyes will lift this stock much higher.
MNTA's debacle following the Lovenox approval is one that they've learned from. This is a different product. Sometimes the past doesn't even rhyme with the future.
Cheers,
MTB
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM